Deleted Tweets From Scott Gottlieb, R-D.C.

Opioid addiction is a complex brain disorder involving alterations in the neuronal circuits underlying the ability to process reward, motivate actions and regulate emotions and desires. https://t.co/RVzYPfubi3. While it can be life-threatening, it's treatable with MAT. https://t.co/HKZuHs22Dg

Each of the three MAT drugs have their own unique characteristics. All three options of MATs should be considered and discussed with people seeking OUD treatment in order to identify the one that best suits their individual needs.

Methadone helps the brain into thinking it’s still getting the abused drug but the person doesn’t get the same high. Patients must visit the clinic daily to take the oral drug under appropriate supervision until they are stable enough for take-home doses. https://t.co/cA9DR0Sz8C

Naltrexone is available in oral and extended-release injectable formulations. It works differently than the other two MATs. If a person using naltrexone relapses and uses the abused drug, naltrexone blocks the euphoric and sedative effects, preventing feelings of euphoria.

Buprenorphine, like methadone, suppresses and reduces cravings for the abused drug. It can come in a pill form or sublingual tablet placed under the tongue, among other dosage forms. But like naltrexone, there is no supervised administration. https://t.co/klI6aPhmrQ

MAT products have risks, including an interaction with drugs classified as central nervous system depressants, such as benzodiazepines. When taken together, they can suppress breathing, increasing the risk of overdose and potentially lead to death. https://t.co/8XFeWJ9fQV

It’s important to recognize that MAT isn’t just about taking your medicine at the proper dose. MAT products work best when coupled with counseling, vocational training, psychosocial therapy, family support and connections to community services. https://t.co/Rz6IOJpWZh

Despite the benefits, MAT is underutilized. Only about 20% of persons with OUDs receive any kind of treatment, according to the Substance Abuse and Mental Health Services Administration’s 2016 National Survey on Drug Use and Health. https://t.co/XFvccKK0tz. https://t.co/dhDQA7qQAu

We recently launched the campaign #stopMATstigma to help the public, patients, healthcare professionals learn more about the availability and proper use of MAT and break the stigma that keeps many Americans who are seeking a life of sobriety from reaching their goals. https://t.co/Zo52G1EpC5

Several barriers exist to the use of MATs. Some clinicians lack training in identifying and treating OUD. And there are negative attitudes and misunderstandings about the medication, including the belief that MATs merely replace one addiction with another. https://t.co/QWk21lhX1c

RT @FDAOncology: This summer, our OCE Scholars learned about cancer drug development by meeting with FDA mentors, visiting a CBER la… https://t.co/1NDDOSUhPq

RT @FDASpox: RECALL: #FDA is working with Hostess Brands to recall Cookies 'n Crème Brownies because they don't list "egg" as an… https://t.co/v3sSAxkvtp

#FDA issued new guidance today aimed at promoting the development of novel treatments for opioid use disorder. We lay out additional, meaningful clinical endpoints where drugs can prove benefit in pursuing approval; such as reduction in overdose or craving https://t.co/QOCgyDkj8G

At #FDA, we've outlined a series of new policies in recent months to help spur the more efficient development of safe, effective gene therapy products; and ensure manufacturing quality through new technologies: https://t.co/P1sxiSxNaa

RT @SecAzar: The evidence is clear: medication-assisted treatment works. @US_FDA's new guidance has the potential to bring new m… https://t.co/KyRVfmeero

New #CDC study in @ELSpharma shows #FLUVAX reduces risk of severe #FLU illness among adults. More in: https://t.co/t3cMWkD6S8

RT @FDASpox: #FDA took new steps to encourage development of novel medication-assisted treatment (MAT) drugs for opioid use diso… https://t.co/P3YOx0R7ox

3/5 We know there’s great interest in new treatment options that result in meaningful outcomes for individuals with OUD. We believe this guidance is an important step in fostering development of new treatment options that help patients achieve a number of real-world outcomes.

THREAD: 1/5 Today, #FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD): https://t.co/MvC4YaVg9N

2/5 New draft guidance outlines ways for drug developers to consider measuring/demonstrating the effectiveness and benefits of new or existing MAT products. Today’s guidance is part of #FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT

Opioid addiction is a complex brain disorder involving alterations in the neuronal circuits underlying the ability to process reward, motivate actions and regulate emotions and desires. https://t.co/RVzYPfubi3. While it can be life-threatening, it's treatable with MAT. https://t.co/HKZuHs22Dg

Each of the three MAT drugs have their own unique characteristics. All three options of MATs should be considered and discussed with people seeking OUD treatment in order to identify the one that best suits their individual needs.

Methadone helps the brain into thinking it’s still getting the abused drug but the person doesn’t get the same high. Patients must visit the clinic daily to take the oral drug under appropriate supervision until they are stable enough for take-home doses. https://t.co/cA9DR0Sz8C

Naltrexone is available in oral and extended-release injectable formulations. It works differently than the other two MATs. If a person using naltrexone relapses and uses the abused drug, naltrexone blocks the euphoric and sedative effects, preventing feelings of euphoria.

Buprenorphine, like methadone, suppresses and reduces cravings for the abused drug. It can come in a pill form or sublingual tablet placed under the tongue, among other dosage forms. But like naltrexone, there is no supervised administration. https://t.co/klI6aPhmrQ

MAT products have risks, including an interaction with drugs classified as central nervous system depressants, such as benzodiazepines. When taken together, they can suppress breathing, increasing the risk of overdose and potentially lead to death. https://t.co/8XFeWJ9fQV

It’s important to recognize that MAT isn’t just about taking your medicine at the proper dose. MAT products work best when coupled with counseling, vocational training, psychosocial therapy, family support and connections to community services. https://t.co/Rz6IOJpWZh

Despite the benefits, MAT is underutilized. Only about 20% of persons with OUDs receive any kind of treatment, according to the Substance Abuse and Mental Health Services Administration’s 2016 National Survey on Drug Use and Health. https://t.co/XFvccKK0tz. https://t.co/dhDQA7qQAu

We recently launched the campaign #stopMATstigma to help the public, patients, healthcare professionals learn more about the availability and proper use of MAT and break the stigma that keeps many Americans who are seeking a life of sobriety from reaching their goals. https://t.co/Zo52G1EpC5

Several barriers exist to the use of MATs. Some clinicians lack training in identifying and treating OUD. And there are negative attitudes and misunderstandings about the medication, including the belief that MATs merely replace one addiction with another. https://t.co/QWk21lhX1c

RT @FDAOncology: This summer, our OCE Scholars learned about cancer drug development by meeting with FDA mentors, visiting a CBER la… https://t.co/1NDDOSUhPq

RT @FDASpox: RECALL: #FDA is working with Hostess Brands to recall Cookies 'n Crème Brownies because they don't list "egg" as an… https://t.co/v3sSAxkvtp

#FDA issued new guidance today aimed at promoting the development of novel treatments for opioid use disorder. We lay out additional, meaningful clinical endpoints where drugs can prove benefit in pursuing approval; such as reduction in overdose or craving https://t.co/QOCgyDkj8G

At #FDA, we've outlined a series of new policies in recent months to help spur the more efficient development of safe, effective gene therapy products; and ensure manufacturing quality through new technologies: https://t.co/P1sxiSxNaa

RT @SecAzar: The evidence is clear: medication-assisted treatment works. @US_FDA's new guidance has the potential to bring new m… https://t.co/KyRVfmeero

New #CDC study in @ELSpharma shows #FLUVAX reduces risk of severe #FLU illness among adults. More in: https://t.co/t3cMWkD6S8

RT @FDASpox: #FDA took new steps to encourage development of novel medication-assisted treatment (MAT) drugs for opioid use diso… https://t.co/P3YOx0R7ox

3/5 We know there’s great interest in new treatment options that result in meaningful outcomes for individuals with OUD. We believe this guidance is an important step in fostering development of new treatment options that help patients achieve a number of real-world outcomes.

THREAD: 1/5 Today, #FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD): https://t.co/MvC4YaVg9N

2/5 New draft guidance outlines ways for drug developers to consider measuring/demonstrating the effectiveness and benefits of new or existing MAT products. Today’s guidance is part of #FDA’s ongoing commitment to promote more widespread development, access to and adoption of MAT